UBS has downgraded Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to "Neutral" from "Buy" given uncertainty around its key Eylea franchise. Brokerage slashed price target to $738 from $1130.

UBS analyst Peter Grom lowered the firm’s price target on Molson Coors (TAP) to $58 from $60 and keeps a Neutral rating on the shares.

UBS analyst Peter Grom lowered the firm’s price target on Scotts Miracle-Gro (SMG) to $72 from $77 and keeps a Neutral rating on the shares.

UBS analyst Patrick Rafaisz upgraded Forbo Holding AG (FORN:SW) stock from Neutral to Buy, despite lowering the price target ...

The infrastructure unit under Chow Tai Fook Enterprises said it will apply to list the new shares on the Hong Kong exchange.

Investing.com -- UBS downgraded Saint Gobain (EPA: SGOB) to Neutral from Buy in a note Thursday, citing limited upside ...

The Nifty moved within a range and ended higher for the second consecutive day on Wednesday. Experts believe that the US CPI ...

UBS has also revised its price target for JD Sports, reducing it by 34% to 103 pence from 155 pence. This adjustment reflects ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Palantir Technologies Inc (PLTR) stock saw a modest uptick, ending the day at $65.91 which represents a slight increase of $0.93 or 1.43% from the prior close of $64.98. The stock opened at $67.18 and ...

Altria Group Inc (MO) stock saw a modest uptick, ending the day at $51.36 which represents a slight increase of $0.51 or 1.00% from the prior close of $50.85. The stock opened at $50.96 and touched a ...

Stocks surged on Wednesday after the latest consumer price index report showed core inflation unexpectedly slowed in December ...